La Jolla Pharmaceutical Co
F:LJPP
Balance Sheet
Balance Sheet Decomposition
La Jolla Pharmaceutical Co
La Jolla Pharmaceutical Co
Balance Sheet
La Jolla Pharmaceutical Co
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
3
|
9
|
49
|
127
|
66
|
91
|
173
|
88
|
21
|
47
|
|
| Cash Equivalents |
3
|
9
|
49
|
127
|
66
|
91
|
173
|
88
|
21
|
47
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
6
|
9
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
6
|
9
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
6
|
6
|
|
| Other Current Assets |
0
|
0
|
2
|
1
|
2
|
3
|
5
|
5
|
3
|
6
|
|
| Total Current Assets |
3
|
9
|
50
|
128
|
67
|
94
|
181
|
98
|
37
|
67
|
|
| PP&E Net |
0
|
0
|
0
|
2
|
3
|
25
|
22
|
34
|
1
|
0
|
|
| PP&E Gross |
0
|
0
|
0
|
2
|
3
|
25
|
0
|
34
|
1
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
1
|
2
|
0
|
10
|
1
|
1
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
13
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
20
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
20
|
20
|
|
| Total Assets |
3
N/A
|
9
+156%
|
51
+480%
|
129
+156%
|
71
-45%
|
120
+69%
|
204
+71%
|
132
-35%
|
72
-45%
|
101
+40%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
1
|
1
|
3
|
7
|
12
|
9
|
4
|
3
|
2
|
|
| Accrued Liabilities |
0
|
0
|
1
|
2
|
3
|
6
|
16
|
20
|
10
|
10
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
3
|
|
| Total Current Liabilities |
0
|
1
|
2
|
5
|
10
|
19
|
26
|
25
|
12
|
18
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
13
|
142
|
164
|
148
|
150
|
|
| Total Liabilities |
0
N/A
|
1
+450%
|
2
+91%
|
5
+129%
|
10
+104%
|
31
+219%
|
168
+438%
|
188
+12%
|
160
-15%
|
168
+5%
|
|
| Equity | |||||||||||
| Common Stock |
11
|
10
|
7
|
7
|
7
|
7
|
7
|
4
|
4
|
4
|
|
| Retained Earnings |
447
|
465
|
487
|
529
|
607
|
722
|
921
|
1 037
|
1 077
|
1 057
|
|
| Additional Paid In Capital |
440
|
463
|
528
|
646
|
661
|
803
|
950
|
977
|
985
|
986
|
|
| Total Equity |
3
N/A
|
8
+141%
|
49
+530%
|
125
+157%
|
61
-51%
|
88
+45%
|
36
-59%
|
56
N/A
|
88
-57%
|
67
+24%
|
|
| Total Liabilities & Equity |
3
N/A
|
9
+156%
|
51
+480%
|
129
+156%
|
71
-45%
|
120
+69%
|
204
+71%
|
132
-35%
|
72
-45%
|
101
+40%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
0
|
4
|
15
|
18
|
18
|
22
|
26
|
27
|
27
|
27
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|